<PAGE>   1


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q/A

(Mark One)

  X      Quarterly report pursuant to Section 13 or 15(d) of the Securities
-----
         Exchange Act of 1934. For the quarterly period ended June 30, 1997.

         Transition report pursuant to Section 13 or 15(d) of the Securities 
-----
         Exchange Act of 1934.  For the transition period from     to     .
                                                              -----  ----- 

                         Commission File Number: 0-19749

                              CHEMTRAK INCORPORATED

    Delaware                                                 77-0295388
-------------------------------                          -----------------------
(State or other jurisdiction of                           (I.R.S Employer)
incorporation or organization)                           Identification No.)

                    929 E. Arques Avenue, Sunnyvale, CA 94086
                    -----------------------------------------
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (408) 773-8156

           Securities registered pursuant to Section 12(g) of the Act:

                          Common Stock $.001 par value
                          ----------------------------
                                (Title of Class)



<PAGE>   2


                              CHEMTRAK INCORPORATED
                                      INDEX



<TABLE>
<CAPTION>
PART I.        FINANCIAL INFORMATION                                                         PAGE
                                                                                             ----
                                                                                              NO.
                                                                                              ---

<S>                                                                                         <C>  
               Item 1:  Financial Statements

               Condensed Balance Sheets as of June 30, 1997 and December 31, 1996              3

               Condensed Statements of Operations for the three and six months ended
               June 30, 1997 and 1996                                                          4

               Condensed Statements of Cash Flows for the six months ended
               June 30, 1997 and 1996                                                          5

               Notes to Condensed Financial Statements                                       6-7

SIGNATURES                                                                                    13
</TABLE>


EXHIBITS



                                       2
<PAGE>   3



                             CHEMTRAK INCORPORATED
                            CONDENSED BALANCE SHEETS



                                     ASSETS


<TABLE>
<CAPTION>
                                                                                       June 30, 1997      December 30, 1996
                                                                                        ------------        ------------
                                                                                         (unaudited)           (Note)
<S>                                                                                     <C>                 <C>         
Current assets:
   Cash and cash equivalents                                                            $  1,875,000        $  4,125,000
   Short-term investments                                                                         --             567,000
   Accounts receivable, net                                                                  520,000             485,000
   Inventories                                                                             1,523,000             540,000
   Prepaid expenses and other current assets                                                 131,000             320,000
                                                                                        ------------        ------------
      Total current assets                                                                 4,049,000           6,037,000
   Property and equipment, net                                                             2,286,000           2,738,000
   Other assets                                                                               66,000              66,000
                                                                                        ------------        ------------
Total assets                                                                            $  6,401,000        $  8,841,000
                                                                                        ============        ============


                                             LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
   Accounts payable                                                                     $    248,000        $    289,000
   Accrued payroll and benefits                                                              165,000             199,000
   Other accrued liabilities                                                                 791,000             788,000
   Accrued royalties                                                                         149,000             105,000
                                                                                        ------------        ------------
      Total current liabilities                                                            1,353,000           1,381,000

Deferred Revenue                                                                             350,000                  --    

Accrued rent                                                                                 315,000             295,000

Convertible debentures                                                                       506,000           2,135,000

Stockholders' equity:
   Common stock                                                                               13,000              12,000
   Additional paid-in capital                                                             43,160,000          41,375,000
   Deferred compensation                                                                     (39,000)            (49,000)
   Accumulated deficit                                                                   (39,257,000)        (36,308,000)
                                                                                        ------------        ------------
      Total stockholders' equity                                                           3,877,000           5,030,000
                                                                                        ------------        ------------

Total liabilities and stockholders' equity                                              $  6,401,000        $  8,841,000
                                                                                        ============        ============
</TABLE>

        Note:   The balance sheet at December 31, 1996 has been derived from the
audited financial statements at that date, but does not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.



                             See accompanying notes.


                                       3


<PAGE>   4



                              CHEMTRAK INCORPORATED
                       CONDENSED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                         Three months ended                      Six months ended
                                                               June 30,                               June 30,
                                                   --------------------------------        --------------------------------
                                                       1997               1996                1997                 1996
                                                   ------------        ------------        ------------        ------------
<S>                                                <C>                 <C>                 <C>                 <C>         
Net revenues:
    Product sales                                  $    870,000        $    581,000        $  1,478,000        $  1,437,000
    Initial license fee                                      --                  --             333,000                  --
    Funded research and other revenues                       --              25,000             500,000             175,000
                                                   ------------        ------------        ------------        ------------
        Total net revenues                              870,000             606,000           2,311,000           1,612,000

Cost and expenses:
    Cost of product sales                               517,000             824,000           1,221,000           1,555,000
    Research and development                            579,000             729,000           1,032,000           1,473,000
    Marketing, general and administrative             1,530,000           1,179,000           3,153,000           2,273,000
                                                   ------------        ------------        ------------        ------------

        Total costs and expenses                      2,626,000           2,732,000           5,406,000           5,301,000
                                                   ------------        ------------        ------------        ------------

Operating loss                                       (1,756,000)         (2,126,000)         (3,095,000)         (3,689,000)

Interest income and (expense), net                      102,000            (663,000)            146,000            (596,000)
                                                   ------------        ------------        ------------        ------------

Net loss                                           $ (1,654,000)       $ (2,789,000)       $ (2,949,000)       $ (4,285,000)
                                                   ============        ============        ============        ============
Net loss per share                                 $      (0.13)       $      (0.29)       $      (0.24)       $      (0.44)
                                                   ============        ============        ============        ============

Shares used in calculating per share amounts         12,855,000           9,773,000          12,470,000           9,743,000
                                                   ============        ============        ============        ============
</TABLE>


                                       4


<PAGE>   5


                              CHEMTRAK INCORPORATED
                       CONDENSED STATEMENTS OF CASH FLOWS
                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                                                 Six months ended
                                                                                     June 30,
                                                                       -------------------------------------
                                                                              1997                1996
                                                                       -----------------   -----------------
<S>                                                                       <C>                   <C>         
Operating activities:
   Net loss                                                               $  (2,949,000)        $(4,285,000)
   Adjustment to reconcile net loss to net cash and
     cash equivalents used in operating activities:
       Depreciation and amortization                                            403,000             430,000
       Interest expense and financing charges
       on convertible debentures                                                105,000             619,000
       Accrued rent                                                              20,000              27,000
       Stock option compensation and other                                           --               2,000
       Loss on disposal of assets                                               170,000                  --
   Changes in operating assets and liabilities:
       Accounts receivable                                                      (35,000)           (364,000)
       Inventories                                                             (983,000)           (266,000)
       Prepaid expenses and other current assets                                189,000             167,000
       Accounts payable                                                         (41,000)           (183,000)
       Accrued payroll and benefits                                             (34,000)             36,000
       Deferred Revenue                                                         350,000                  --
       Accrued royalties and other accrued liabilities                           47,000             349,000

                                                                       -----------------   -----------------
            Net cash and cash equivalents 
              used in operating activities                                   (2,758,000)         (3,468,000)
                                                                       -----------------   -----------------


Investing activities:
   Proceeds from available-for-sale securities                                  567,000             514,000
   Acquisition of property and equipment, net                                  (121,000)           (190,000)
                                                                       -----------------   -----------------

            Net cash and cash equivalents provided
             by investing activities                                            446,000             324,000
                                                                       -----------------   -----------------

Financing activities:
   Net proceeds from issuance of convertible debentures                              --           4,700,000
   Issuance of common stock                                                      62,000             182,000
                                                                       -----------------   -----------------

            Net cash and cash equivalents provided
             by financing activities                                             62,000           4,882,000
                                                                       -----------------   -----------------

Net increase (decrease) in cash and cash equivalents                         (2,250,000)          1,738,000
Cash and cash equivalents at beginning of period                              4,125,000           4,251,000
                                                                       -----------------   -----------------
Cash and cash equivalents at end of period                                $   1,875,000         $ 5,989,000
                                                                       =================   =================


Supplemental disclosure of non-cash financing activities:
Conversion of convertible debentures and accrued
   interest to common stock                                               $   1,629,000           $      --
                                                                       =================   =================
</TABLE>

                             See accompanying notes.


                                       5


<PAGE>   6


                              CHEMTRAK INCORPORATED

                     NOTES TO CONDENSED FINANCIAL STATEMENTS

                                  June 30, 1997

                                   (unaudited)

Note 1.  Basis of Presentation

        The accompanying unaudited financial statements include all adjustments
consisting of normal recurring adjustments which the Company's management
believes to be necessary to fairly present the Company's financial position as
of June 30, 1997, and the results of operations for the three and six month
periods ended June 30, 1997.


        The operating results of the interim periods presented are not
necessarily indicative of the results for the full year. The accompanying
financial statements should be read in conjunction with the financial statements
for the year ended December 31, 1996, included in the ChemTrak Incorporated
Annual Report on Form 10-K for the fiscal year ended December 31, 1996 (the
"Form 10-K"), and the 1996 Annual Report to Stockholders (the "Annual Report").
The information set forth in the accompanying balance sheet as of December 31,
1996, has been derived from the audited balance sheet included in the
above-referenced Form 10-K and Annual Report.


Note 2.  Revenue Recognition

        Product revenues are generally recognized at the time of shipment to
customers or distributors. Initial license revenues are recorded when earned,
which is upon signing of the license agreement, confirmation of collectibility
and when no future obligations remain. The Company recognizes license
termination and conversion fees when earned, which is upon signing of the
license agreement, confirmation of collectibility and when no future obligations
remain. These fees are recognized as operating income to offset the operating
expenses that have been recorded prior to termination or conversion of the
contract. These operating expenses were incurred by the Company to build and
supply the expected product pipeline as part of the original license agreement.
The Company recognized license termination and conversion fees of $3,600,000 in
1995. 
 


Note 3.  Deferred Revenue

       In April 1997, the Company received a $350,000 payment from Astra Merck,
Inc. This payment was for product that the Company had produced, but not yet
shipped.  

Note 4.  Net Loss Per Share


        Net loss per share is computed using the weighted average number of
shares outstanding. Common equivalent shares from stock options are excluded in
the computation as their effect is antidilutive.

        In February 1997, the Financial Accounting Standards Board issued
Statement No. 128, Earnings per Share, which ChemTrak is required to adopt on
December 31, 1997. At that time, the Company will be required to change the
method currently used to compute loss per share and to restate all prior
periods. Under the new requirements for calculating primary loss per share, the
dilutive effect of stock options will be excluded. The primary loss per share
for the three and six month period ended June 30, 1997 and June 30, 1996 would
not change as reported. The impact of Statement 128 is expected not to have a
material effect on fully diluted loss per share. 


                                       6


<PAGE>   7


                              CHEMTRAK INCORPORATED

               NOTES TO CONDENSED FINANCIAL STATEMENTS (continued)

                                  June 30, 1997

                                   (unaudited)



Note 5.  Inventories

        Inventories are stated at the lower of standard cost (which approximates
actual costs on a first-in, first-out basis) or market. Inventories consisted of
the following:


<TABLE>
<CAPTION>
                    June 30, 1997    December 31,1996
                      ----------       ----------
<S>                   <C>              <C>       
Raw materials.......  $  728,000       $  289,000
Work in process.....     182,000           63,000
Finished goods......     613,000          188,000
                      ----------       ----------
  Total.............  $1,523,000       $  540,000
                      ==========       ==========
</TABLE>


Note 6.  Convertible Debentures

        In May 1996, the Company issued $5,000,000 of convertible debentures
resulting in net proceeds to the company of $4,700,000 after deducting selling
commissions. The debentures, which are due in May 1998, are convertible into
common stock at the lower of 110% of the average closing prices during the
ten-day trading period ending with the initial debenture funding date, or 82.5
percent of the similarly-defined average ten-day market price ending with the
conversion date. The Company has the option to convert the amount of periodic
interest due on the convertible debentures, computed at the rate of 7.5% per
annum, into common stock of the Company in lieu of cash payments. Through June
30, 1997, all interest obligations on the debentures have been settled by the
issuance of common stock.

        The accompanying financial statements reflect deemed non-cash interest
expense of $875,000 ($656,250 and $218,750 in the quarters ended June 30, 1996
and September 30, 1996, respectively).

        As of June 30, 1997, aggregate principal amount of $4,605,000 had been
converted into 3,013,000 shares of common stock and approximately 84,436 shares
were issued to settle interest obligations.


                                       7


<PAGE>   8


                              CHEMTRAK INCORPORATED

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                       CONDITION AND RESULTS OF OPERATIONS



        The following Management's Discussion and Analysis of Financial
Condition and Results of Operations contains forward-looking statements which
involve risks and uncertainties. The Company's actual results could differ
materially from those anticipated in these forward-looking statements as a
result of certain factors, including those set forth in the Company's 1996 Form
10K and elsewhere in this document.


OVERVIEW

        ChemTrak began marketing the AccuMeter(R) Cholesterol Test to the United
States physicians office market in May 1991, following receipt of clearance from
the FDA, and to the international consumer retail and physicians' office
laboratory market in October 1991. In March 1993, the Company received clearance
from the FDA for the United States consumer retail market. In January 1994, the
Company began marketing the AccuMeter(R) Cholesterol Self-Test through United
States consumer catalogs and signed a license and supply agreement with Direct
Access Diagnostics ("DAD"), a Johnson & Johnson company, to market the Company's
Total Cholesterol Test to over-the-counter retail outlets in North America. In
December 1995, the Company regained the exclusive rights to market its Total
Cholesterol Test in the United States retail market and re-launched the product
in January 1996 under the trade name of CholesTrak(R).

        In April 1997, the Company entered into an agreement with Parents Alert
to distribute a home drug test kit. Under terms of the agreement, ChemTrak will
assume responsibility for nationwide marketing and distribution of the Parent's
Alert Home Drug Test Service. In return, Parent's Alert will receive royalty
payments and consulting payments from ChemTrak for the use of its name. Product
distribution is expected to begin in the third quarter of this year.

        In March 1997, ChemTrak announced its entry into the colorectal disease
testing market with the introduction of ColoCARE(R), a Home Test to Detect the
Early Warning Signs of Colorectal Disease. The Company began shipments of
ColoCARE(R) during the first quarter of 1997.

        In July 1996, the Company received clearance from the FDA to market its
first test for infectious diseases, the H. pylori test for use in the
physicians' office laboratory market. The first shipment to Astra Merck, Inc.
as part of the 1995 agreement, is now expected to be delivered in the third
quarter of 1997.


                                       8


<PAGE>   9


        In January of 1997, ChemTrak announced a pan-European license with
Selfcare Inc. of Waltham, Massachusetts to market the AWARE(TM)home HIV test
service in Europe. As part of the agreement Selfcare will pay for the cost of
regulatory submissions in each of the countries of Europe. Selfcare, does
however, have the option to terminate the agreement if the FDA does not approve
ChemTrak's AWARE(TM) home HIV test service in 1997. In 1995, the Company
acquired technology and filed with the FDA its pre-market approval application
("PMA") for the Company's AWARE(TM) home HIV test service. In June 1997, the FDA
requested additional information regarding the PMA Filing. The Company is
evaluating the FDA information request and the market opportunity for the
product. 

        As of June 30, 1997, ChemTrak had an accumulated deficit of
approximately $39,257,000. The ability of the Company to achieve profitability
is highly dependent upon numerous factors including, but not limited to, the
Company's ability to directly market and distribute its cholesterol, H. Pylori,
home drug test kit, and colorectal products in the United States, successful
completion of the Company's regulatory approval process to market products
under development, and the Company's ability to provide product in sufficient,
cost effective quantities. Due to the uncertainty of these factors, it is
difficult to reliably predict when such profitability may occur, if at all.
Until such time as it achieves profitability, the Company is likely to require
additional capital to finance its operations.

        The development and marketing of consumer medical devices is capital
intensive. The Company has funded its operations to date through product sales,
funded research and other revenues, and public and private equity and debt
financings. The Company will require substantial additional funding in order to
complete the development and marketing activities in which it is currently
engaging, and to launch these products in the consumer marketplace. The Company
intends to seek additional funding through collaborative agreements with
corporate partners or through additional equity or debt financings. There can be
no assurance that the Company will be able to enter into such arrangements on
acceptable terms, or at all.

        The Company has historically experienced significant fluctuations in its
operating results and anticipates that these fluctuations may continue. The
market price of the shares of the Company's common stock, like that of other
emerging medical technology companies, has been highly volatile. Various factors
including, but not limited to, fluctuations in the Company's operating results,
technical and regulatory developments, and general market and economic factors,
may have a significant effect on the market price of the Company's common stock.


                                       9


<PAGE>   10


RESULTS OF OPERATIONS

NET REVENUES

        Net revenues increased to $870,000 for the three months ended June 30,
1997 from $606,000 for the three months ended June 30, 1996. Product sales
increased to $870,000 in the three months ended June 30, 1997 from $581,000 in
the three months ended June 30, 1996, primarily due to higher shipments of
CholesTrak(R). Net revenues increased to $2,311,000 for the six months ended
June 30, 1997 from $1,612,000 for the same period last year. The variance is
due to an initial license fee of $333,000 and to Funded research and other
revenues increasing to $500,000 for the six months ended June 30, 1997 from
$175,000 for the six months ended June 30, 1996. Included in funded research
and other revenues, for the six month period ending June 30, 1997, is a
$500,000 milestone payment from Astra Merck, Inc., who will market ChemTrak's
H. pylori test as HpChek. Included in initial license fees is a $333,000
license fee from Selfcare, Inc. of Waltham, Mass. for the Pan-European
licensing and distribution agreement for marketing the AWARE home HIV test
service.  COST OF PRODUCT SALES

        Cost of product sales for the three months ended June 30, 1997,
decreased to $517,000 from $824,000 for the three months ended June 30, 1996.
For the six months ended June 30, 1997, cost of product sales decreased to
$1,221,000 from $1,555,000 for the six months ended June 30, 1996.  The decrease
for both the three and six month periods was primarily due to the sale of
product with lower recorded product cost and cost efficiencies from higher sales
volumes, and an effort by management to reduce manufacturing costs.

        Product gross margin as a percentage of product sales increased to 41%
for the three months ended June 30, 1997 from a negative 42% for the same period
in 1996. Product gross margin as a percentage of product sales increased to 17%
for the six months ended June 30, 1997 from a negative 8% for the six months
ended June 30, 1996. These increases were primarily due to the reasons noted in
the prior paragraph.



RESEARCH AND DEVELOPMENT


        Research and development expenses decreased to $579,000 in the three
months ended June 30, 1997 from $729,000 for the three months ended June 30,
1996. For the six months ended June 30, 1997, research and development expenses
decreased to $1,032,000 from $1,473,000 for the six month period ended June 30,
1996. These decreases were primarily due to fewer clinical studies, reduction in
use of supplies and cost savings from a departmental reorganization.


                                       10


<PAGE>   11


MARKETING, GENERAL AND ADMINISTRATION


        Marketing, general and administrative expenses increased to $1,530,000
for the three months ended June 30, 1997 from $1,179,000 for the three months
ended June 30, 1996. For the six months ended June 30, 1997, marketing, general
and administration expenses were $3,153,000 as compared to $2,273,000 for the
six months ended June 30, 1996. These increases were primarily due to selling
and advertising expenses associated with the Company's CholesTrak total
cholesterol test.


INTEREST INCOME AND (EXPENSE), NET

        Net interest income and (expense) increased to $102,000 of net interest
income  for the three months ended June 30, 1997 from $663,000 of net interest
expense for the three months ended June 30, 1996, and increased to $146,000 of
net interest income for the six months ended June 30, 1997 from $596,000 of net
interest expense for the six months ended June 30, 1996. These increases were
due to the inclusion of non-cash interest expense in the 1996 periods from the
convertible debentures that the Company issued during May 1996.



LIQUIDITY AND CAPITAL RESOURCES

        From August 1985 through January 1992 the Company was financed through
private placements of equity securities. In February 1992, the Company completed
its initial public offering, raising approximately $23,500,000 net of issuance
costs.

        At June 30, 1997, the Company had approximately $1,875,000 in cash.

        The Company had convertible debentures outstanding of $506,000 at June
30, 1997.

        The Company believes that its existing capital resources, together with
internally generated funds and funded research, will need to be augmented by
funds received from third parties, through collaboration agreements or equity or
debt financing to complete the development and marketing activities in which it
is currently engaged, and to launch these products in the consumer marketplace.
If such funding cannot be obtained, the Company may be required to implement
significant cost cutting measures to ensure the continuity of operations. The
Company has begun implementing certain cost cutting measures. At the Company's
current spending levels, the Company believes that available cash balances will
be sufficient to fund the Company's operations through October of 1997. The
Company's success is dependent on its ability to achieve profitable operations,
reduce discretionary operating expenses and to obtain additional funds to
support its operations. There can be no assurance that the Company will achieve
profitable operations or successfully reduce discretionary expenses by a
sufficient amount on a timely basis or that additional funds will be available
when and as required by the Company on acceptable terms or at all.


                                       11


<PAGE>   12


                              CHEMTRAK INCORPORATED

                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this amendment to the quarterly report
on Form 10Q for the quarter ended June 30, 1997 to be signed on its behalf by
the undersigned thereunto duly authorized.


Date:   March 10, 1998              CHEMTRAK INCORPORATED


                                    /s/ Donald V. Fluken
                                    -----------------------------------------
                                    Donald V. Fluken
                                    Chief Financial Officer
                                   (Principal Financial and Accounting Officer)